^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    α1 adrenergic receptor antagonist

    Related drugs:
    8d
    Enhanced antiproliferative and anti-inflammatory effects of combined metformin, tadalafil, and tamsulosin in a rat model of testosterone-induced benign prostatic hyperplasia. (PubMed, Life Sci)
    although individual treatments provided benefits, their combined use enhanced therapeutic outcomes through modulation of oxidative stress, inflammation, and androgenic activity in BPH management.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IGF2 (Insulin-like growth factor 2) • TGFB1 (Transforming Growth Factor Beta 1) • TGFB2 (Transforming Growth Factor Beta 2)
    |
    metformin
    10d
    Exploring the key molecular mechanisms and immune microenvironment of oxidative stress-related pathways in pancreatic neuroendocrine tumor combining scRNA-seq and bulk RNA. (PubMed, Discov Oncol)
    Through integrated multi-omics analysis, we established that oxidative stress pathways may drive pNET progression through a coordinated mechanism involving metabolic reprogramming (via BCL2L1 and PHGDH downregulation), immune microenvironment remodeling (through altered dendritic cell and NK cell function), and complex regulatory networks. BCL2L1 and PHGDH represent potential diagnostic biomarkers and candidate therapeutic targets that require experimental validation, providing new directions for precision medicine in pNET.
    Journal
    |
    BCL2L1 (BCL2-like 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • KCNQ1OT1 (KCNQ1 Opposite Strand/Antisense Transcript 1) • PHGDH (Phosphoglycerate Dehydrogenase) • MIR15A (MicroRNA 15a)
    |
    Cabometyx (cabozantinib tablet)
    15d
    A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate (clinicaltrials.gov)
    P4, N=136, Recruiting, The Fourth Affiliated Hospital of Zhejiang University School of Medicine
    New P4 trial
    16d
    Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery (clinicaltrials.gov)
    P4, N=20, Recruiting, Mayo Clinic | Trial primary completion date: Dec 2027 --> Jan 2027
    Trial primary completion date
    22d
    A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults (clinicaltrials.gov)
    P1, N=72, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    23d
    Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Pain in the Pediatric Population (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Phoenix Children's Hospital | N=60 --> 0 | Unknown status --> Withdrawn
    Enrollment change • Trial withdrawal
    1m
    Study to Evaluate the Drug-drug Interaction Between IY001 and IY002 in Healthy Adult Male Subjects. (clinicaltrials.gov)
    P1, N=43, Completed, Il-Yang Pharm. Co., Ltd.
    New P1 trial
    |
    finasteride
    1m
    A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients (clinicaltrials.gov)
    P4, N=400, Recruiting, Pharmazz, Inc. | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Nov 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    1m
    Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion (clinicaltrials.gov)
    P4, N=500, Not yet recruiting, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
    New P4 trial
    |
    mirabegron
    1m
    A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent (clinicaltrials.gov)
    P3, N=430, Not yet recruiting, Pharmazz, Inc. | Trial completion date: Oct 2026 --> Oct 2027
    Trial completion date
    1m
    ARAB: Intermittent vs Daily Tamsulosin for LUTS/BPH (clinicaltrials.gov)
    P4, N=288, Not yet recruiting, Mansoura University
    New P4 trial • Head-to-Head
    1m
    Exploring acenocoumarol and silodosin in non-small cell lung cancer: Insights into EGFR-linked signaling mechanisms. (PubMed, F1000Res)
    In the xenograft study, tumor size, body weight, and organ weight were significantly attenuated by the test drugs compared with the standard cisplatin. KRAS and ERK2 are components of EGFR-associated signaling pathways. Hence, acenocoumarol and silodosin can be further explored as repurposed candidates in future preclinical and clinical studies.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CASP3 (Caspase 3)
    |
    cisplatin • silodosin